Guide price only. Final cost is confirmed after assessment.
Meniscus replacement at the London Cartilage Clinic represents a cutting-edge surgical solution for individuals with severe meniscal damage or previous removal. This procedure involves replacing the damaged or missing meniscus - a crucial cartilage in the knee joint - with a donor graft. This surgery is crucial for maintaining knee stability, reducing pain, and delaying arthritis onset.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertise
Meniscus replacement is considered when the native meniscus is severely damaged or absent, and symptoms continue despite structured non-operative care.
The goal is to restore cushioning and load distribution inside the knee, reducing pain and helping delay further cartilage wear.
Surgery is usually performed arthroscopically, using specialised instruments to prepare the knee and secure the donor graft in a stable position.
Recovery timelines vary, often ranging from 3 to 9 months depending on tissue healing, rehabilitation quality, and activity goals.
At London Cartilage Clinic, treatment planning and follow-up are handled by a specialist cartilage team to maximise graft protection and long-term knee function.
Meniscus replacement is a surgical procedure to replace a damaged or missing meniscus in the knee, aiming to restore joint stability and alleviate pain.
Ideal candidates are between 30 to 55 years old, not obese, with stable knee ligaments and minimal knee arthritis.
Recovery varies, typically ranging from 3 to 9 months, depending on the individual’s condition and adherence to rehabilitation.
While rare, risks include knee stiffness, bleeding, infection, or the need for additional surgery.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
For active patients with cartilage defects, OATS and microfracture produce similar results at two years, but ten-year data favour OATS decisively: 14% treatment failure against 38% for microfracture—a gap reflecting tissue type, as fibrocartilage wears under athletic load whilst genuine hyaline cartilage endures.
Since its introduction in 2013, ChondroFiller has recorded zero serious adverse device effects across more than 19,000 treated cases, with a device complaint rate of 0.06%.
High-grade cartilage lesions on MRI (ICRS Grade 3–4) appear in 5–10% of symptom-free adults; cartilage grade and symptoms do not correlate, and severity alone does not determine whether surgery is required.
